Recently, a similar approach has been proposed for prostate cancer, and it has been demonstrated that, in prostate cellular models, celecoxib reduces cell growth, induces apoptosis, and promotes EGFR degradation. The gene discussed is EGFR; the disease is Familial prostate cancer.